Senseonics and Beta Bionics launch year-long Eversense 365 sensor with iLet pump
Senseonics and Beta Bionics said on November 16 that the iLet Bionic Pancreas now runs on the Eversense 365 implanted sensor, pairing a one-year CGM with automated insulin dosing.
Pulse, covering wearables and health sensors
, 3 min read
365 dayshow long one Eversense 365 sensor is designed to last
What to know
- Senseonics and Beta Bionics announced the commercial launch of the integrated system on November 16, meeting the Q4 2026 target set in September.
- Eversense 365 is implanted under the skin by a clinician, is cleared in the US for adults 18 and older, and needs a weekly fingerstick calibration after day 14.
- The companies plan to connect Eversense 365 to Beta Bionics' Mint tubeless patch pump later; no price or date was given.
Senseonics and Beta Bionics said on Monday, November 16, that they have commercially launched the iLet Bionic Pancreas working with the Eversense 365 continuous glucose monitor (CGM). It pairs a CGM sensor designed to last a full year with an insulin pump whose algorithm decides every dose on its own. The announcement came in a joint release from the two companies. No independent report had added detail by Tuesday evening, so the facts below are the companies' own.
The launch meets the timeline the companies set out in September, when Senseonics announced the partnership and said it planned to bring out the combined system in the fourth quarter of 2026.
What the system does
The iLet is an automated insulin delivery (AID) system. It reads glucose values from a CGM and uses Beta Bionics' algorithm to dose insulin. The companies say users do not count carbohydrates or give manual correction doses, though a footnote adds that the user "must be carb aware." Beta Bionics describes its algorithm as the first FDA-cleared one that sets every insulin dose by itself.
Eversense 365 works differently from the stick-on sensors most people know from Dexcom and Abbott. A clinician inserts a small sensor under the skin, and the wearer puts a removable smart transmitter on top that sends readings to a phone every five minutes. One sensor is designed to last up to 365 days.
The trade-off is calibration. According to Senseonics' indication text, Eversense 365 still needs a fingerstick blood glucose reading for calibration about once a week after day 14, and whenever symptoms don't match the CGM readings or the wearer is taking tetracycline-class antibiotics.
Who can use it
Eversense 365 is cleared in the US and approved in Europe for people with diabetes aged 18 and older, and it is prescription only. The release does not say whether the iLet integration is offered outside the US, does not list prices or insurance coverage, and does not give a separate FDA clearance date for the combination. It points people to a sign-up page for getting started.
The release gives no new accuracy data. Its claims of fewer sensor changes and fewer false alerts rest on Senseonics' user guide and a 2018 accuracy study of an earlier Eversense sensor.
What comes next
The companies say they will also connect Eversense 365 to Mint, Beta Bionics' tubeless patch pump, at an unspecified date. Senseonics called iLet a step on from its first pump integration.
The launch lands in a busy week for diabetes devices. The FDA cleared MiniMed Fit, MiniMed's first tubeless pump, and Tandem disclosed clearance for a tubeless Mobi. Abbott's Libre Duo glucose and ketone sensor is also heading for US launch. For how a device like this reaches the market, see our explainer on FDA clearance versus approval.
Why it matters
Most CGMs used with automated insulin systems are stick-on patches that wearers replace themselves. Pairing iLet with a year-long implanted sensor gives adults an option with far fewer sensor changes, in exchange for a clinic insertion and weekly fingersticks. It also gives Senseonics, a small player next to Dexcom and Abbott, a second pump partner. Those two companies' sensors are the default in most AID systems, and sensors like Biolinq Shine are adding more competition.
This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.
Sources
- Senseonics and Beta Bionics Launch Eversense 365 and iLet Bionic Pancreas Integration, Senseonics and Beta Bionics via GlobeNewswire, Nov 16, 2026
- Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense 365 with the iLet Bionic Pancreas, Senseonics, Sep 14, 2026
Glucose and metabolic techWearablesFDA and health regulation
Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.